Guarantor Financial Information Condensed Consolidated Statements of Cash Flows (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 28, 2013		Dec. 29, 2012		Dec. 31, 2011
Cash flows from operating activities:
Net income	$ 108,967		$ 130,770		$ 169,418
Earnings in investments in subsidiaries	0		0		0
Other operating cash flows	101,754		118,767		71,446
Net cash provided by operating activities	210,721		249,537		240,864
Cash flows from investing activities:
Capital expenditures	(118,307)	[1]	(115,413)	[1]	(60,153)	[1]
Acquisitions, net of cash acquired	(734,075)		(3,000)		(1,754)
Investment in unconsolidated subsidiary	(44,959)		(43,424)		(23,305)
Notes Receivables From Affiliates	0
Gross proceeds from sale of property, plant and equipment and other assets	2,358		3,870		1,529
Proceeds from Insurance Settlement	1,981		4,272		0
Payments related to routes and other intangibles	(2,423)		(137)		0
Net cash used by investing activities	(895,425)		(153,832)		(83,683)
Cash flows from financing activities:
Proceeds from long-term debt	344,704		0		0
Payments on long-term debt	(580)		(30,032)		(270,009)
Borrowings from revolving credit facility	293,235		0		131,000
Payments on revolving credit facility	(5,000)		0		(291,000)
Borrowings From Affiliates	0
Deferred loan costs	(13,320)		0		(399)
Issuance of common stock	840,558		72		293,117
Proceeds from Contributions from Parent	0		0		0
Minimum withholding taxes paid on stock awards	(3,289)		(4,084)		(1,281)
Excess tax benefits from stock-based compensation	1,138		2,652		1,125
Net cash provided/(used) in financing activities	1,457,446		(31,392)		(137,447)
Effect of Exchange Rate on Cash and Cash Equivalents	(5,134)		0		0
Net increase/(decrease) in cash and cash equivalents	767,608		64,313		19,734
Cash and cash equivalents at beginning of year	103,249		38,936		19,202
Cash and cash equivalents at end of year	870,857		103,249		38,936
Issuer [Member]
Cash flows from operating activities:
Net income	108,967		130,770		169,418
Earnings in investments in subsidiaries	(105,178)		(119,953)		(145,950)
Other operating cash flows	135,315		175,098		184,027
Net cash provided by operating activities	139,104		185,915		207,495
Cash flows from investing activities:
Capital expenditures	(45,173)		(49,619)		(23,835)
Acquisitions, net of cash acquired	0		(3,000)		(1,754)
Investment in unconsolidated subsidiary	(600,537)		(43,449)		(23,330)
Notes Receivables From Affiliates	0
Gross proceeds from sale of property, plant and equipment and other assets	1,329		2,083		961
Proceeds from Insurance Settlement	1,531		1,305
Payments related to routes and other intangibles	(2,423)		(137)
Net cash used by investing activities	(645,273)		(92,817)		(47,958)
Cash flows from financing activities:
Proceeds from long-term debt	200,000
Payments on long-term debt	0		(30,000)		(270,000)
Borrowings from revolving credit facility	245,000				131,000
Payments on revolving credit facility	(5,000)				(291,000)
Borrowings From Affiliates	0
Deferred loan costs	(11,916)				(399)
Issuance of common stock	840,558		72		293,117
Proceeds from Contributions from Parent	0		0		0
Minimum withholding taxes paid on stock awards	(3,289)		(4,084)		(1,281)
Excess tax benefits from stock-based compensation	1,138		2,652		1,125
Net cash provided/(used) in financing activities	1,266,491		(31,360)		(137,438)
Effect of Exchange Rate on Cash and Cash Equivalents	0
Net increase/(decrease) in cash and cash equivalents	760,322		61,738		22,099
Cash and cash equivalents at beginning of year	96,945		35,207		13,108
Cash and cash equivalents at end of year	857,267		96,945		35,207
Guarantors [Member]
Cash flows from operating activities:
Net income	107,317		121,321		146,584
Earnings in investments in subsidiaries	0		0		0
Other operating cash flows	(39,459)		(56,445)		(114,532)
Net cash provided by operating activities	67,858		64,876		32,052
Cash flows from investing activities:
Capital expenditures	(68,716)		(65,794)		(36,318)
Acquisitions, net of cash acquired	(121,440)		0		0
Investment in unconsolidated subsidiary	(63,115)		0		0
Notes Receivables From Affiliates	(370,996)
Gross proceeds from sale of property, plant and equipment and other assets	1,029		1,787		568
Proceeds from Insurance Settlement	450		2,967
Payments related to routes and other intangibles	0		0
Net cash used by investing activities	(622,788)		(61,040)		(35,750)
Cash flows from financing activities:
Proceeds from long-term debt	0
Payments on long-term debt	(82)		(32)		(9)
Borrowings from revolving credit facility	0				0
Payments on revolving credit facility	0				0
Borrowings From Affiliates	0
Deferred loan costs	0				0
Issuance of common stock	0		0		0
Proceeds from Contributions from Parent	555,552		0		0
Minimum withholding taxes paid on stock awards	0		0		0
Excess tax benefits from stock-based compensation	0		0		0
Net cash provided/(used) in financing activities	555,470		(32)		(9)
Effect of Exchange Rate on Cash and Cash Equivalents	0
Net increase/(decrease) in cash and cash equivalents	540		3,804		(3,707)
Cash and cash equivalents at beginning of year	5,577		1,773		5,480
Cash and cash equivalents at end of year	6,117		5,577		1,773
Non-guarantors [Member]
Cash flows from operating activities:
Net income	(2,139)		(1,368)		(634)
Earnings in investments in subsidiaries	0		0		0
Other operating cash flows	5,898		114		1,951
Net cash provided by operating activities	3,759		(1,254)		1,317
Cash flows from investing activities:
Capital expenditures	(4,418)		0		0
Acquisitions, net of cash acquired	(612,635)		0		0
Investment in unconsolidated subsidiary	(44,959)		(43,424)		(23,305)
Notes Receivables From Affiliates	0
Gross proceeds from sale of property, plant and equipment and other assets	0		0		0
Proceeds from Insurance Settlement	0		0
Payments related to routes and other intangibles	0		0
Net cash used by investing activities	(662,012)		(43,424)		(23,305)
Cash flows from financing activities:
Proceeds from long-term debt	144,704
Payments on long-term debt	(498)		0		0
Borrowings from revolving credit facility	48,235				0
Payments on revolving credit facility	0				0
Borrowings From Affiliates	370,996
Deferred loan costs	(1,404)				0
Issuance of common stock	0		0		0
Proceeds from Contributions from Parent	108,100		43,449		23,330
Minimum withholding taxes paid on stock awards	0		0		0
Excess tax benefits from stock-based compensation	0		0		0
Net cash provided/(used) in financing activities	670,133		43,449		23,330
Effect of Exchange Rate on Cash and Cash Equivalents	(5,134)
Net increase/(decrease) in cash and cash equivalents	6,746		(1,229)		1,342
Cash and cash equivalents at beginning of year	727		1,956		614
Cash and cash equivalents at end of year	7,473		727		1,956
Eliminations [Member]
Cash flows from operating activities:
Net income	(105,178)		(119,953)		(145,950)
Earnings in investments in subsidiaries	105,178		119,953		145,950
Other operating cash flows	0		0		0
Net cash provided by operating activities	0		0		0
Cash flows from investing activities:
Capital expenditures	0		0		0
Acquisitions, net of cash acquired	0		0		0
Investment in unconsolidated subsidiary	663,652		43,449		23,330
Notes Receivables From Affiliates	370,996
Gross proceeds from sale of property, plant and equipment and other assets	0		0		0
Proceeds from Insurance Settlement	0		0
Payments related to routes and other intangibles	0		0
Net cash used by investing activities	1,034,648		43,449		23,330
Cash flows from financing activities:
Proceeds from long-term debt	0
Payments on long-term debt	0		0		0
Borrowings from revolving credit facility	0				0
Payments on revolving credit facility	0				0
Borrowings From Affiliates	(370,996)
Deferred loan costs	0				0
Issuance of common stock	0		0		0
Proceeds from Contributions from Parent	(663,652)		(43,449)		(23,330)
Minimum withholding taxes paid on stock awards	0		0		0
Excess tax benefits from stock-based compensation	0		0		0
Net cash provided/(used) in financing activities	(1,034,648)		(43,449)		(23,330)
Effect of Exchange Rate on Cash and Cash Equivalents	0
Net increase/(decrease) in cash and cash equivalents	0		0		0
Cash and cash equivalents at beginning of year	0		0		0
Cash and cash equivalents at end of year	$ 0		$ 0		$ 0

[1] Excludes the capital assets acquired as part of the acquisition of assets related to the Terra Transaction and the Rothsay Acquisition in fiscal 2013 of approximately $167.0 million and the BioPur acquisition in fiscal 2012 of approximately $0.6 million